3-(3-(3-(4-(1-Aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)propanamide

ID: ALA5219229

Chembl Id: CHEMBL5219229

PubChem CID: 139483392

Max Phase: Preclinical

Molecular Formula: C49H50N10O7

Molecular Weight: 891.00

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ncccc1-c1nc2ccc(-c3cccc(CCC(=O)NCCOCCOCCNc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)c3)nc2n1-c1ccc(C2(N)CCC2)cc1

Standard InChI:  InChI=1S/C49H50N10O7/c50-43-35(8-3-22-54-43)44-56-38-16-15-36(55-45(38)58(44)33-13-11-32(12-14-33)49(51)20-4-21-49)31-6-1-5-30(29-31)10-18-40(60)53-24-26-66-28-27-65-25-23-52-37-9-2-7-34-42(37)48(64)59(47(34)63)39-17-19-41(61)57-46(39)62/h1-3,5-9,11-16,22,29,39,52H,4,10,17-21,23-28,51H2,(H2,50,54)(H,53,60)(H,57,61,62)

Standard InChI Key:  NONHSXRQZRRMFV-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5219229

    ---

Associated Targets(Human)

AKT1 Tchem CRBN/AKT1 (26 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 891.00Molecular Weight (Monoisotopic): 890.3864AlogP: 4.66#Rotatable Bonds: 18
Polar Surface Area: 238.78Molecular Species: BASEHBA: 14HBD: 5
#RO5 Violations: 2HBA (Lipinski): 17HBD (Lipinski): 7#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.59CX Basic pKa: 9.65CX LogP: 4.11CX LogD: 2.03
Aromatic Rings: 6Heavy Atoms: 66QED Weighted: 0.06Np Likeness Score: -0.76

References

1. Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J..  (2022)  Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.,  65  (20.0): [PMID:36197750] [10.1021/acs.jmedchem.2c01454]

Source